Establishment Labs Holdings Inc. | Small-cap | Healthcare
$43.64
9.10%
| Establishment Labs Stock Comparison:
Establishment Labs vs Abbott LaboratoriesEstablishment Labs vs Boston ScientificEstablishment Labs vs EnovisEstablishment Labs vs QuidelOrthoEstablishment Labs vs UFP TechnologiesEstablishment Labs vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 51.3M
Gross Profit 35.3M 68.76%
Operating Income -14.1M -27.50%
Net Income -16.6M -32.35%
EPS (Diluted) $-0.57

Balance Sheet Metrics

Total Assets 333.4M
Total Liabilities 294.8M
Shareholders Equity 38.6M
Debt to Equity 7.65

Cash Flow Metrics

Operating Cash Flow -24.2M
Free Cash Flow -21.8M

Revenue & Profitability Trend

Establishment Labs Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i166.0M165.2M161.7M126.7M84.7M
Cost of Goods Sold i56.5M58.2M55.1M41.3M32.2M
Gross Profit i109.5M107.0M106.6M85.4M52.5M
Gross Margin % i66.0%64.8%65.9%67.4%62.0%
Operating Expenses
Research & Development i19.7M26.4M20.3M18.3M13.8M
Selling, General & Administrative i139.8M145.6M126.0M92.2M66.6M
Other Operating Expenses i-----
Total Operating Expenses i159.5M172.0M146.3M110.5M80.4M
Operating Income i-50.0M-65.0M-39.7M-25.1M-27.9M
Operating Margin % i-30.1%-39.4%-24.5%-19.8%-33.0%
Non-Operating Items
Interest Income i1.5M1.0M87.0K23.0K15.0K
Interest Expense i20.8M15.4M11.8M9.1M9.4M
Other Non-Operating Income-15.3M816.0K-21.5M-5.5M-743.0K
Pre-tax Income i-84.6M-78.6M-72.8M-39.7M-38.0M
Income Tax i-32.0K-81.0K2.4M1.4M104.0K
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-84.6M-78.5M-75.2M-41.1M-38.1M
Net Margin % i-51.0%-47.5%-46.5%-32.5%-45.0%
Key Metrics
EBITDA i-56.2M-58.3M-38.4M-27.3M-26.9M
EPS (Basic) i$-3.00$-3.07$-3.08$-1.72$-1.63
EPS (Diluted) i$-3.00$-3.07$-3.08$-1.72$-1.63
Basic Shares Outstanding i2816176125600029244577932397272223316102
Diluted Shares Outstanding i2816176125600029244577932397272223316102

Income Statement Trend

Establishment Labs Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i90.3M40.0M66.4M53.4M84.5M
Short-term Investments i-----
Accounts Receivable i65.0M46.9M35.4M24.4M19.1M
Inventory i78.8M79.5M36.6M28.4M23.2M
Other Current Assets2.6M2.4M1.6M1.8M2.1M
Total Current Assets i243.0M174.9M149.9M113.3M132.3M
Non-Current Assets
Property, Plant & Equipment i5.6M3.4M3.7M2.2M2.6M
Goodwill i14.1M8.9M5.5M5.3M5.1M
Intangible Assets i11.7M8.0M4.6M4.4M4.1M
Long-term Investments-----
Other Non-Current Assets7.3M4.7M1.3M558.0K664.0K
Total Non-Current Assets i103.8M93.7M61.2M26.3M24.1M
Total Assets i346.8M268.6M211.1M139.5M156.4M
Liabilities
Current Liabilities
Accounts Payable i44.8M41.6M20.0M14.5M9.7M
Short-term Debt i1.5M773.0K688.0K402.0K788.0K
Current Portion of Long-term Debt-----
Other Current Liabilities1.7M----
Total Current Liabilities i68.3M57.2M39.0M31.9M25.9M
Non-Current Liabilities
Long-term Debt i223.8M191.5M178.7M53.8M51.8M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities102.0K147.0K-44.0K-47.0K
Total Non-Current Liabilities i225.5M193.1M180.3M56.9M55.5M
Total Liabilities i293.7M250.2M219.2M88.8M81.4M
Equity
Common Stock i420.4M315.6M223.6M219.7M213.5M
Retained Earnings i-444.7M-360.1M-281.6M-206.4M-165.2M
Treasury Stock i2.9M2.9M2.9M2.9M2.9M
Other Equity-----
Total Shareholders Equity i53.1M18.4M-8.2M50.7M75.0M
Key Metrics
Total Debt i225.3M192.2M179.3M54.2M52.5M
Working Capital i174.8M117.8M110.9M81.4M106.4M

Balance Sheet Composition

Establishment Labs Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-84.6M-78.5M-75.2M-41.1M-38.1M
Depreciation & Amortization i7.6M4.9M4.3M4.1M3.7M
Stock-Based Compensation i15.4M14.9M13.4M10.4M5.7M
Working Capital Changes i-20.0M-35.1M-19.9M-9.6M7.8M
Operating Cash Flow i-72.0M-87.9M-72.8M-34.8M-19.8M
Investing Activities
Capital Expenditures i-6.1M-7.9M-2.9M-2.4M-2.1M
Acquisitions i-50.0K----
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-6.2M-7.9M-3.4M-2.9M-3.8M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i24.5M0168.1M00
Debt Repayment i00-71.7M-175.0K-277.0K
Financing Cash Flow i123.4M84.1M96.4M-531.0K63.4M
Free Cash Flow i-74.1M-113.1M-86.4M-34.3M-16.4M
Net Change in Cash i45.3M-11.7M20.2M-38.2M39.8M

Cash Flow Trend

Establishment Labs Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -14.55
Forward P/E -24.24
Price to Book 50.89
Price to Sales 6.53
PEG Ratio 1.80

Profitability Ratios

Profit Margin -49.89%
Operating Margin -27.50%
Return on Equity -261.18%
Return on Assets -12.78%

Financial Health

Current Ratio 2.84
Debt to Equity 993.34
Beta 0.83

Per Share Data

EPS (TTM) $-3.08
Book Value per Share $0.79
Revenue per Share $6.17

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
esta1.2B-14.5550.89-261.18%-49.89%993.34
Abbott Laboratories 229.7B16.564.5430.93%32.43%26.50
Boston Scientific 156.3B62.796.9711.55%13.55%53.09
Enovis 1.8B-2.110.70-28.25%-37.80%56.75
QuidelOrtho 1.8B-0.910.63-15.64%-17.01%100.33
UFP Technologies 1.7B25.444.3919.29%11.40%46.98

Financial data is updated regularly. All figures are in the company's reporting currency.